Insmed(INSM)盘前上涨7.07% PAH吸入式疗法3期临床试验取得积极新进展

金吾财讯06-11

金吾财讯 | 制药公司Insmed(INSM)盘前涨逾7%，最新报98.38美元，涨幅7.07%。消息面上，该公司新近宣布，其其用于治疗肺动脉高压(PAH)的吸入式疗法(TPIP)3期临床试验取得最新进展，目前正在持续招募受试者。该研究旨在评估每日一次吸入药物对改善成年患者日常活动能力的疗效。若该后期临床试验取得成功，将有助于Insmed实现收入来源多元化，并直接与强生、United Therapeutics等在PAH领域的行业巨头展开激烈竞争。

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2642007044?lang=zh_CN&edition=full","thumbnail":"https://static.szfiu.com/news/20250107/YjZmMjQ4YmQ4ZjZmMDRlNTI1MzFkZTUxNzM2MjM3NjU3NDA0.png","is_english":false,"pubTime":"2026-06-11 17:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2642007044","market":"nz","top_or_hot":-1,"title":"Insmed(INSM)盘前上涨7.07% PAH吸入式疗法3期临床试验取得积极新进展","media":"金吾财讯","content":"<html><body><p>金吾财讯 | 制药公司<a href=\"https://laohu8.com/S/INSM\">Insmed</a>(INSM)盘前涨逾7%，最新报98.38美元，涨幅7.07%。消息面上，该公司新近宣布，其其用于治疗肺动脉高压(PAH)的吸入式疗法(TPIP)3期临床试验取得最新进展，目前正在持续招募受试者。该研究旨在评估每日一次吸入药物对改善成年患者日常活动能力的疗效。若该后期临床试验取得成功，将有助于Insmed实现收入来源多元化，并直接与<a href=\"https://laohu8.com/S/JNJ\">强生</a>、United <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>等在PAH领域的行业巨头展开激烈竞争。</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Insmed(INSM)盘前上涨7.07% PAH吸入式疗法3期临床试验取得积极新进展</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nInsmed(INSM)盘前上涨7.07% PAH吸入式疗法3期临床试验取得积极新进展\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-06-11 17:04 北京时间&nbsp;&nbsp;&nbsp;<a href=301418><strong>金吾财讯</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>金吾财讯 | 制药公司Insmed(INSM)盘前涨逾7%，最新报98.38美元，涨幅7.07%。消息面上，该公司新近宣布，其其用于治疗肺动脉高压(PAH)的吸入式疗法(TPIP)3期临床试验取得最新进展，目前正在持续招募受试者。该研究旨在评估每日一次吸入药物对改善成年患者日常活动能力的疗效。若该后期临床试验取得成功，将有助于Insmed实现收入来源多元化，并直接与强生、United ...</p>\n\n<a href=\"301418\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0053671581.USD","symbol_name":"摩根大通美国小盘成长股 A(dist)","start_time":0,"source_url":"301418","article_id":"2642007044","we_media_id":"1086022552","thumbnails":["https://static.szfiu.com/news/20250107/YjZmMjQ4YmQ4ZjZmMDRlNTI1MzFkZTUxNzM2MjM3NjU3NDA0.png"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2642007044","pubTimestamp":1781168653,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"金吾财讯","introduction":"「金吾财讯」以精准用户需求为切入点，打造一站式港美股投资细分领域品牌。依托战略合作伙伴凤凰网财经，将港美股内容传播到全球华人圈。","home_visible":1,"id":"1086022552","head_image":"https://static.tigerbbs.com/19a93586c3b023ec6ebfed568990555c"},"summary":"金吾财讯 | 制药公司Insmed(INSM)盘前涨逾7%，最新报98.38美元，涨幅7.07%。消息面上，该公司新近宣布，其其用于治疗肺动脉高压(PAH)的吸入式疗法(TPIP)3期临床试验取得最新进展，目前正在持续招募受试者。该研究旨在评估每日一次吸入药物对改善成年患者日常活动能力的疗效。若该后期临床试验取得成功，将有助于Insmed实现收入来源多元化，并直接与强生、United Therapeutics等在PAH领域的行业巨头展开激烈竞争。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU0053671581.USD":"摩根大通美国小盘成长股 A(dist)","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","BK4139":"生物科技","INSM":"Insmed","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC"},"translate_title":"Insmed (INSM) Up 7.07% Premarket PAH Inhalation Therapy Phase 3 Clinical Trial Makes Positive New Progress","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"INSM":1.5},"content_text":"金吾财讯 | 制药公司Insmed(INSM)盘前涨逾7%，最新报98.38美元，涨幅7.07%。消息面上，该公司新近宣布，其其用于治疗肺动脉高压(PAH)的吸入式疗法(TPIP)3期临床试验取得最新进展，目前正在持续招募受试者。该研究旨在评估每日一次吸入药物对改善成年患者日常活动能力的疗效。若该后期临床试验取得成功，将有助于Insmed实现收入来源多元化，并直接与强生、United Therapeutics等在PAH领域的行业巨头展开激烈竞争。","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2642007044","isCrawlerRequest":true}